Involvement of PKA and Sp1 in the induction of p27Kip1 by tamoxifen

Biochemical Pharmacology

Volumn 66, Issue 3, 2003, Pages 371-377

  Lee, Te Hsiu ^a   Chang, Hui Chiu ^a   Chuang, Lea Yea ^a   Hung, Wen Chun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Lung cancer; p27Kip1; Protein kinase A; Sp1; Tamoxifen

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CALPHOSTIN C; CELL PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN KINASE C INHIBITOR; PROTEIN P27; TAMOXIFEN;

ARTICLE; ASSAY; BASE PAIRING; CANCER CELL; CONTROLLED STUDY; DNA BINDING; GENE DELETION; HALF LIFE TIME; HUMAN; HUMAN CELL; LUNG CANCER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN STABILITY; STIMULATION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE;

EID: 0041695737     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00258-2     Document Type: Article

References (38)

1. Jordan V.C., Lababidi M.K., Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. Natl. Cancer Inst. 83:1991;492-496.
2. Henderson B.E., Ross R.K., Pike M.C. Hormonal chemoprevention of cancer in women. Science. 259:1993;633-638.
3. Couldwell W.T., Weiss M.H., DeGiorgio C.M., Weiner L.P., Hinton D.R., Ehresmann G.R., Conti P.S., Apuzzo M.L. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery. 32:1993;485-489.
4. Croxtall J.D., Emmas C., White J.O., Choudhary Q., Flower R.J. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem. Pharmacol. 47:1994;197-202.
5. Del Prete S.A., Maurer L.H., O'Donnell J., Forcier R.J., LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 68:1984;1403-1405.
6. Lee T.H., Chuang L.Y., Hung W.C. Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells. Oncogene. 18:1999;4269-4274.
7. Polyak K., Lee M.H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66.
8. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
9. Hengst L., Dulic V., Slingerland J.M., Lees E., Reed S.I. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. U.S.A. 91:1994;5291-5295.
10. Koff A., Ohtsuki M., Polyak K., Roberts J.M., Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science. 260:1993;536-539.
11. Kato J.Y., Matsuoka M., Polyak K., Massague J., Sherr C.J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 79:1994;487-496.
12. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
13. Lloyd R.V., Erickson L.A., Jin L., Kulig E., Qian X., Cheville J.C., Scheithauer B.W. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol. 154:1999;313-323.
14. Ponce-Castaneda M.V., Lee M.H., Latres E., Polyak K., Lacombe L., Montgomery K., Mathew S., Krauter K., Sheinfeld J., Massague J. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 55:1995;1211-1214.
15. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:1997;3381-3385.
16. Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., Roberts J.M. Expression of cell-cycle regulators p27Kip1 and cyclin E alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:1997;222-225.
17. Tsihlias J., Kapusta L.R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos G.C., Klotz L.H., Slingerland J.M. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58:1998;542-548.
18. Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res. 88:1997;625-629.
19. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1:1999;193-199.
20. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yew P.R., Draetta G.F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
21. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11:1997;1464-1478.
22. Shirane M., Harumiya Y., Ishida N., Hirai A., Miyamoto C., Hatakeyama S., Nakayama K., Kitagawa M. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 274:1999;13886-13893.
23. Minami S., Ohtani-Fujita N., Igata E., Tamaki T., Sakai T. Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett. 411:1997;1-6.
24. Inoue T., Kamiyama J., Sakai T. Sp1 and NF-Y synergistically mediate the effect of Vitamin D(3) in the p27(Kip1) gene promoter that lacks Vitamin D response elements. J. Biol. Chem. 274:1999;32309-32317.
25. Lee T.H., Chuang L.Y., Hung W.C. Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells. Oncogene. 19:2000;3766-3773.
26. Hung W.C., Chang H.C., Pan M.R., Lee T.H., Chuang L.Y. Induction of p27(Kip1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol. Pharmacol. 58:2000;1398-1403.
27. Millard S.S., Yan J.S., Nguyen H., Pagano M., Kiyokawa H., Koff A. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J. Biol. Chem. 272:1997;7093-7098.
28. Hengst L., Reed S.I. Translational control of p27Kip1 accumulation during the cell cycle. Science. 271:1996;1861-1864.
29. Kamiyama J., Inoue T., Ohtani-Fujita N., Minami S., Yamagishi H., Sakai T. The ubiquitous transcription factor NF-Y positively regulates the transcription of human p27Kip1 through a CCAAT box located in the 5′-upstream region of the p27Kip1 gene. FEBS Lett. 455:1999;281-285.
30. Moro A., Perea S.E., Pantoja C., Santos A., Arana M.D., Serrano M. IFNalpha 2b induces apoptosis and proteasome-mediated degradation of p27Kip1 in a human lung cancer cell line. Oncol. Rep. 8:2001;425-429.
31. de Koning J.P., Soede-Bobok A.A., Ward A.C., Schelen A.M., Antonissen C., van Leeuwen D., Lowenberg B., Touw I.P. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip 1). Oncogene. 19:2000;3290-3298.
32. Medema R.H., Kops G.J., Bos J.L., Burgering B.M. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 404:2000;782-787.
33. Yang W., Shen J., Wu M., Arsura M., FitzGerald M., Suldan Z., Kim D.W., Hofmann C.S., Pianetti S., Romieu-Mourez R., Freedman L.P., Sonenshein G.E. Repression of transcription of the p27(Kip 1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 20:2001;1688-1702.
34. Rohlff C., Ahmad S., Borellini F., Lei J., Glazer R.I. Modulation of transcription factor Sp1 by cAMP-dependent protein kinase. J. Biol. Chem. 272:1997;21137-21141.
35. Yatabe Y., Masuda A., Koshikawa T., Nakamura S., Kuroishi T., Osada H., Takahashi T., Mitsudomi T., Takahashi T. p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res. 58:1998;1042-1047.
36. Catzavelos C., Tsao M.S., DeBoer G., Bhattacharya N., Shepherd F.A., Slingerland J.M. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 59:1999;684-688.
37. Chen Y.M., Perng R.P., Yang K.Y., Lin W.C., Wu H.W., Liu J.M., Tsai C.M., Whang-Peng J. A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer. Am. J. Clin. Oncol. 23:2000;13-17.
38. Chen Y.M., Perng R.P., Yang K.Y., Lin W.C., Wu H.W., Liu J.M., Tsai C.M., Whang-Peng J. Phase II study of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy in patients with non-small-cell lung cancer failing previous chemotherapy. Lung Cancer. 29:2000;139-146.